🟢 Axsome Therapeutics is trading 6% up in pre-market after 46% Q2 revenue growth

Axsome Therapeutics is trading 6.04% up at $234.24 after August 10, 2026, Q2 results highlighted 46% revenue growth and accelerating AUVELITY demand.

• AUVELITY sales rose 51% year over year to $180.3 million; Alzheimer’s agitation prescriptions increased 126% following the June launch.
• Investors appear to be emphasizing commercial momentum, cash runway, and FDA acceptance of the AXS-12 NDA despite slightly below-consensus revenue and EPS.